Beranda › Kanker Payudara › Connecticut › New Haven
Uji klinis Kanker Payudara di New Haven, CT
37 studi untuk Kanker Payudara mencari peserta di lokasi sekitar New Haven (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- Yale Cancer Center, New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Menerima pesertaFase 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Menerima pesertaFase 1/2
- Yale University School of Medicine, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Menerima pesertaFase 1
- Yale University - Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Yale Cancer Center, New Haven
Study of AVZO-021 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Menerima pesertaFase 1
- Yale Cancer Center, New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Menerima pesertaFase 3
- Yale Cancer Center ( Site 0060), New Haven
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Menerima pesertaFase 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale University/Yale Cancer Center/Yale School of Medicine, New Haven
- Smilow Cancer Hospital Care Center - North Haven, North Haven · 7 mi jauhnya
- dan 2 lainnya
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Menerima pesertaFase 3
- Research Site, New Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Menerima pesertaFase 3
- Clinical Trial Site, New Haven
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Menerima peserta
- Yale Cancer Center, New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Menerima pesertaFase 1
- Yale University School Of Medicine, New Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Menerima pesertaFase 2
- Yale Cancer Center Clinical Trials Office, New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Menerima pesertaFase 3
- Yale New Haven Hospital- Yale Cancer Center, New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Menerima pesertaFase 1/2
- Yale Cancer Center, New Haven
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Menerima pesertaFase 3
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Menerima pesertaFase 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi jauhnya
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi jauhnya
- dan 1 lainnya
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Menerima pesertaFase 3
- Smilow Cancer Hospital at Yale New Haven, New Haven
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- Yale Cancer Center, New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Menerima pesertaFase 2
- Yale University Cancer Center, New Haven
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Menerima peserta
- Yale Cancer Center, New Haven
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Menerima pesertaFase 2
- Yale Cancer Center at Yale University School of Medicine, New Haven
- Smilow Cancer Hospital Care center at North Haven, North Haven · 7 mi jauhnya
- Smilow Cancer Hospital Care center at Derby, Derby · 8 mi jauhnya
- dan 1 lainnya
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Menerima pesertaFase 3
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Menerima pesertaFase 3
- Yale University, New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Yale University, Yale Cancer Center, New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Menerima pesertaFase 1
- Yale Cancer Center Smilow Cancer Hospital, New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
Menerima pesertaStudi observasional
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Menerima pesertaFase 3
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Smilow Cancer Hospital - North Haven, North Haven · 7 mi jauhnya
- Smilow Cancer Hospital - Derby, Derby · 8 mi jauhnya
- dan 1 lainnya
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Menerima pesertaFase 2
- Yale Cancer Center, New Haven
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Menerima pesertaFase 3
- Yale-New Haven Hospital Saint Raphael Campus, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi jauhnya
- dan 4 lainnya
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Menerima pesertaFase 1/2
- Yale University, Yale Cancer Center, New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Menerima peserta
- Yale University, New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Menerima pesertaFase 2
- Yale University, New Haven
The Cancer of the Pancreas Screening-5 CAPS5)Study
Menerima pesertaFase 3
- Yale University, New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Menerima pesertaFase 1
- Yale University, New Haven
Uji klinis Kanker Payudara di kota lain
- New York City, NY134 studi
- Houston, TX126 studi
- Boston, MA111 studi
- Nashville, TN80 studi
- Los Angeles, CA72 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Durham, NC63 studi
- Queens, NY63 studi
- Chicago, IL58 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Studi lain di New Haven
- Kanker Paru Non-Sel Kecil41 studi
- Kanker (semua jenis)33 studi
- Kanker Metastatik23 studi
- Kanker Paru22 studi
- Karsinoma Sel Skuamosa Kepala dan Leher22 studi
- Kanker Ovarium21 studi
- Kanker Kolorektal20 studi
- Kanker Prostat20 studi
- Overdosis Opioid18 studi
- Gangguan Penggunaan Alkohol (AUD)17 studi
- Leukemia Mieloid Akut17 studi
- Kanker Pankreas16 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.